Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Alterity Therapeutics Limited - Sponsored ADR (ATHE : NSDQ)
 
 • Company Description   
Alterity Therapeutics Limited is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset consists ATH434, to treat various Parkinsonian disorders. Alterity Therapeutics Limited, formerly known as PRANA BIO, is based in MELBOURNE, Australia.

Number of Employees: 10

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.15 Daily Weekly Monthly
20 Day Moving Average: 26,917 shares
Shares Outstanding: 8.87 (millions)
Market Capitalization: $36.80 (millions)
Beta: 0.71
52 Week High: $5.87
52 Week Low: $1.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -13.74% -18.41%
12 Week 45.29% 21.89%
Year To Date 25.38% 17.44%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Level 14 350 Collins Street
-
Melbourne,C3 VIC 3000
AUS
ph: 61-0-3-9349-4906
fax: 61-3-9348-0377
we-aualterity@we-worldwide.com https://alteritytherapeutics.com
 
 • General Corporate Information   
Officers
David A. Stamler - Chief Executive Officer
Geoffrey Kempler - Chairman
Phillip Allen Hains BBus - Company Secretary and Chief Financial Officer
Lawrence B. Gozlan - Director
Peter A. Marks - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 02155X205
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 8.87
Most Recent Split Date: 1.00 (0.10:1)
Beta: 0.71
Market Capitalization: $36.80 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.34 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 7.26
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - 3.84
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - 0.57
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©